Single-cell biology is reshaping pathological scar research
Pathological scars remain defined by runaway dermal collagen deposition, but the biology behind hypertrophic scars and keloids is no longer viewed through a single-fibroblast lens. The scar is a tissue ecosystem. Mesenchymal cells, endothelial cells, epithelial cells, and immune populations act in concert to sustain a microenvironment that is both profibrotic and proangiogenic, and that cellular choreography helps explain why these lesions persist long after the original wound has closed.
High-throughput sequencing has made that ecosystem visible at a resolution older histology could not provide. Instead of treating scar tissue as a uniform mass of excess collagen, modern transcriptomic approaches expose heterogeneity in cell state, lineage behavior, and local signaling. The practical consequence is important: fibrotic growth in pathological scarring is not simply a matter of too much matrix production, but of a self-reinforcing network of stromal activation, vascular signaling, and immune instruction.
Mesenchymal cells drive the fibrotic core
Mesenchymal cells remain central to the scar phenotype because they are the main architects of extracellular matrix accumulation. In hypertrophic scars and keloids, these cells do not behave like passive structural support; they adopt activated programs that favor collagen synthesis, tissue contraction, and sustained remodeling. Their transcriptional shifts create the scaffold on which the rest of the lesion develops.
A deeper look at this compartment also explains why scars can be stubbornly persistent. Once fibroblasts and related mesenchymal populations enter a pro-fibrotic state, they help maintain the local cues that keep the wound environment activated. This is not a short-lived inflammatory burst. It is a chronic tissue state in which matrix deposition, aberrant repair signaling, and altered mechanoresponses all continue to feed one another.
Some scars never get the message to stop repairing.
Endothelial and epithelial cells help sustain the niche
The vascular component of pathological scars is more than a bystander effect. Endothelial cells contribute to a proangiogenic niche that supports lesion maintenance and likely helps prolong the delivery of signals and nutrients needed by the fibrotic tissue. In a scar that remains biologically active, vascular behavior becomes part of the disease itself rather than a simple accompaniment to repair.
Epithelial cells also sit within this network, shaping the wound surface and influencing the signals exchanged between the epidermis and dermis. Their role matters because cutaneous repair depends on coordinated communication across tissue layers. When that communication is distorted, the healing program can become locked into a prolonged activated state, with epithelial-mesenchymal cross-talk helping to perpetuate abnormal remodeling.
Immune cells are active directors, not passive infiltrates
Immune cells add another level of control to the scar microenvironment. Their presence in pathological scars is not merely inflammatory background noise. These cells help instruct fibroblast behavior, influence angiogenic activity, and shape the cytokine milieu that keeps the lesion biologically active. The review frames immune populations as part of a broader communication system rather than as isolated inflammatory markers.
That perspective is clinically useful because immune-driven fibrosis tends to blur the line between injury response and chronic disease. If immune cells continue to reinforce profibrotic signaling, the scar can behave less like a resolved wound and more like a maintained pathological niche. In that setting, therapies aimed only at collagen suppression may miss upstream drivers that sustain the entire cellular network.
Precision medicine depends on better biomarkers
A biomarker-driven approach offers one route toward more individualized care. The cellular heterogeneity of pathological scars makes blanket treatment strategies increasingly unsatisfying, especially when different lesions may be sustained by different combinations of stromal, vascular, epithelial, and immune signals. Biomarkers could help identify which pathways dominate in a given scar and which patients are more likely to benefit from a specific intervention.
That would move scar management toward stratification instead of repetition. A lesion marked by strong vascular signaling may not respond in the same way as one dominated by immune activation or mesenchymal persistence. Molecular readouts could also help define disease stage, because an actively remodeling scar and a mature, relatively quiescent lesion are biologically distinct targets even when they look similar at the bedside.
Targeted biologics and drug delivery are the next therapeutic test
Precision medicine strategies for pathological scarring extend beyond diagnosis. Targeted biological therapies are increasingly attractive because they can be aligned with the pathways uncovered by high-dimensional profiling. Rather than broadly suppressing wound biology, these approaches aim at the signals that actually sustain the abnormal scar state.
Drug delivery systems add a second advantage: they may improve local exposure while limiting unnecessary systemic effects. In a disorder confined to the skin yet driven by deep molecular complexity, delivery is not a minor technical issue. It is part of the therapy. Localized, controlled, and sustained release platforms could make it possible to concentrate treatment where the pathology lives, while avoiding the inefficiency of systemic dosing for a localized lesion.
The translational challenge is straightforward to state and difficult to solve: a scar is biologically heterogeneous, and therapy has to be equally precise.
Translating cellular maps into bedside treatment will take more than one target
The cellular landscape of pathological scars argues against a one-pathway explanation. Fibrosis, angiogenesis, epithelial signaling, and immune communication are woven together into a single disease process, and each arm can influence the others. That is why the most useful future treatments may combine biologic targeting, biomarker selection, and advanced delivery rather than relying on a single antifibrotic mechanism.
This framework also changes how experimental work should be interpreted. Single-cell and other high-throughput methods do not just catalog cell types; they reveal where therapeutic pressure might be applied to break the cycle of persistent wound activation. For clinicians and investigators, the value lies in converting cellular detail into actionable treatment design, especially for lesions that continue to expand, thicken, or recur despite conventional management.
The remaining task is translational rather than conceptual: identify the dominant cellular programs in a given scar, match them to a targetable pathway, and deliver therapy in a way that can alter the tissue environment before fibrosis becomes self-sustaining.